Condreay LD - Search Results

1

Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.

Condreay LD, Qu XA, Anderson J, Compton C, Ghosh S. Condreay LD, et al. Respir Med. 2019 Aug;155:51-53. doi: 10.1016/j.rmed.2019.06.023. Epub 2019 Jun 29. Respir Med. 2019. PMID: 31299468 Free article.

2

Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.

Condreay L, Huang L, Harris E, Brooks J, Riley JH, Church A, Ghosh S. Condreay L, et al. Respir Med. 2016 May;114:123-6. doi: 10.1016/j.rmed.2016.03.019. Epub 2016 Apr 1. Respir Med. 2016. PMID: 27109822 Free article.

3

No genetic association detected with mepolizumab efficacy in severe asthma.

Condreay L, Chiano M, Ortega H, Buchan N, Harris E, Bleecker ER, Thompson PJ, Humbert M, Gibson P, Yancey S, Ghosh S. Condreay L, et al. Respir Med. 2017 Nov;132:178-180. doi: 10.1016/j.rmed.2017.10.019. Epub 2017 Oct 26. Respir Med. 2017. PMID: 29229094 Free article.

4

No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia.

Condreay LD, Gao C, Bradford E, Yancey SW, Ghosh S. Condreay LD, et al. Respir Med. 2019 Aug;155:26-28. doi: 10.1016/j.rmed.2019.07.004. Epub 2019 Jul 5. Respir Med. 2019. PMID: 31295674 Free article.

5

Genetics plays a limited role in predicting chronic obstructive pulmonary disease treatment response and exacerbation.

Hosking L, Yeo A, Hoffman J, Chiano M, Fraser D, Ghosh S, Lipson DA, Martin N, Condreay LD, Cox C, St Jean P. Hosking L, et al. Among authors: condreay ld. Respir Med. 2021 Oct;187:106573. doi: 10.1016/j.rmed.2021.106573. Epub 2021 Aug 10. Respir Med. 2021. PMID: 34428673 Free article.

6

Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.

Condreay LD, Parham LR, Qu XA, Steinfeld J, Wechsler ME, Raby BA, Yancey SW, Ghosh S. Condreay LD, et al. Rheumatol Int. 2020 Aug;40(8):1301-1307. doi: 10.1007/s00296-020-04523-6. Epub 2020 Feb 3. Rheumatol Int. 2020. PMID: 32009195 Free PMC article. Clinical Trial.

7

ADRB2 p.Thr164Ile association with hospitalization depends upon asthma severity.

Condreay LD, Chiano MN, Li L, Harris E, Fraser DJ, Meyers DA, Bleecker ER, Crim C, Stempel D, Yancey SW, Ghosh S. Condreay LD, et al. J Allergy Clin Immunol. 2019 May;143(5):1962-1965.e4. doi: 10.1016/j.jaci.2019.01.012. Epub 2019 Jan 23. J Allergy Clin Immunol. 2019. PMID: 30682460 Free article. Clinical Trial. No abstract available.

8

Exploring the roles of UGT1A1 and UGT1A3 in oral clearance of GSK2190915, a 5-lipoxygenase-activating protein inhibitor.

Mosteller M, Condreay LD, Harris EC, Ambery C, Beerahee M, Ghosh S. Mosteller M, et al. Among authors: condreay ld. Pharmacogenet Genomics. 2014 Dec;24(12):618-21. doi: 10.1097/FPC.0000000000000090. Pharmacogenet Genomics. 2014. PMID: 25192553

9

Genetic analysis of asthma exacerbations.

Anderson WH, Koshy BT, Huang L, Mosteller M, Stinnett SW, Condreay LD, Ortega H. Anderson WH, et al. Among authors: condreay ld. Ann Allergy Asthma Immunol. 2013 Jun;110(6):416-422.e2. doi: 10.1016/j.anai.2013.04.002. Ann Allergy Asthma Immunol. 2013. PMID: 23706709

10

Genotyping anti-hepatitis B virus drug resistance.

Bourne EJ, Gauthier J, Lopez VA, Condreay LD. Bourne EJ, et al. Among authors: condreay ld. Methods Mol Med. 2004;96:379-85. doi: 10.1385/1-59259-670-3:379. Methods Mol Med. 2004. PMID: 14762283 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page